2,3-双(4-羟苯基)丙腈
| 中文名称 | 2,3-双(4-羟苯基)丙腈 |
|---|---|
| 中文同义词 | 2,3-双(4-羟苯基)丙腈;2,3-双(4-羟基苯基)丙腈 |
| 英文名称 | 2,3-BIS(4-HYDROXYPHENYL)-PROPIONITRILE |
| 英文同义词 | 2,3-BIS(4-HYDROXYPHENYL)-PROPIONITRILE;2,3-bis(p-hydroxyphenyl)propionitrile;propionitrile,2,3-bis(p-hydroxyphenyl);SC-4473;Diarylpropionitrile;2,3-Bis(4-hydroxyphenyl)propanenitrile;2,3-Bis(4-hydroxyphenyl)propiononitrile;4-Hydroxy-alpha-(4-hydroxyphenyl)benzenepropanenitrile |
| CAS号 | 1428-67-7 |
| 分子式 | C15H13NO2 |
| 分子量 | 239.27 |
| EINECS号 | |
| 相关类别 | 合成;抗体-二抗;Miscellaneous;Intracellular receptor;Nuclear Receptors;Diarylpropionitrile |
| Mol文件 | 1428-67-7.mol |
| 结构式 |  |
2,3-双(4-羟苯基)丙腈 性质
| 熔点 | 200.0 to 204.0 °C |
|---|---|
| 沸点 | 449.4±35.0 °C(Predicted) |
| 密度 | 1.256±0.06 g/cm3(Predicted) |
| RTECS号 | UG0900000 |
| 储存条件 | -20°C |
| 溶解度 | DMSO：可溶10mg/mL，澄清 |
| 形态 | 粉末 |
| 酸度系数(pKa) | 9.41±0.26(Predicted) |
| 颜色 | 白色至米色 |
| 水溶解性 | Soluble in 1eq. NaOH (30 mM), ethanol (100 mM), DMSO (100 mM), DMF (~30 mg/ml), and water (0.5 mg/ml at 25°C). |
| 稳定性 | 自购买之日起 1 年内保持稳定。 DMSO 或乙醇溶液可在 -20°C 下保存长达 1 个月。 |
|
ERβ 0.85 nM (EC 50 ) |
DPN has a 70-fold ERα relative binding affinity selectivity, and it is a full ERα agonist with a 78-fold ERα potency selectivity (EC
50
=0.85 nM for ERβ; EC
50
=66 nM for ERα).
DPN (10 nM) prevents morphological alterations from Aβ
1-42
(10 μM)-induced toxicity in cultured cortical neurons.
DPN (0.1-100 nM) decreases ROS levels in a non-dose response manner.
DPN (0.1-100 nM) significantly reduces Aβ
1-42
-stimulated expression of Bax in a non-dose dependent manner.
DPN (0.1-100 nM) reduces activated IL-1 levels induced by Aβ
1-42
treatment on cultured cortical neurons.
DPN (0.1-100 nM) suppresses the Aβ
1-42
-upregulated phosphorylation of JNK and p38.
DPN (10 μg; s.c.; daily; for 11 days) increases swimming and decreases immobility in the FST, and increases TPH protein expression in the dorsal raphe nucleus (DR) in rat model.
| Animal Model: | Adult Sprague-Dawley female rats (220-250 g), ovariectomized animal models |
| Dosage: | 10 μg/rat |
| Administration: | Subcutaneous injections, daily, for 11 days |
| Result: | Increased swimming and decreased immobility in the FST. |